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Summary 
Melanocytes, replenished throughout life by melanocyte stem cells (MSCs), play a critical role in 
pigmentation and melanoma. Here, we reveal a function for the metastasis-associated 
Phosphatase of Regenerating Liver 3 (PRL3) in melanocyte stem cell regeneration. We show 
that PRL3 binds to the RNA helicase DDX21, thereby restricting productive transcription by 
RNAPII at MITF-regulated endolysosomal vesicle genes. In zebrafish, this mechanism controls 
premature melanoblast expansion and differentiation from MSCs. In melanoma patients, 
restricted transcription of this endolysosomal vesicle pathway is a hallmark of PRL3-high 
melanomas. Our work presents the conceptual advance that PRL3-mediated control of 
transcriptional elongation is a differentiation checkpoint mechanism for activated MSCs and has 
clinical relevance for the activity of PRL3 in regenerating tissue and cancer.  
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Introduction 
Stem cell and developmental pathways are often reactivated during regeneration and frequently 
mutated in cancers, providing a lens through which to resolve disease-associated biology 
across different forms of cancers (Sanchez-Vega, et al., 2018). These pathways are conserved 
in zebrafish melanocyte development thereby enabling powerful chemical and genetic in vivo 
screens to discover new therapeutic candidates for melanoma (Cagan, et al., 2019; van 
Rooijen, et al., 2017). 
Melanocytes are pigment cells derived from the neural crest or via a somatic stem cell 
population, and the melanocyte lineage gives rise to melanoma (Mort, et al., 2015). In zebrafish, 
melanocytes emerge during early development from the sox10-expressing neural crest to form 
the embryonic stripe pattern (embryonic melanocytes), while a subpopulation of melanocyte 
stem cells (MSCs), also derived from the neural crest, establish a dormant niche at the site of 
the future dorsal root ganglia (Singh and Nusslein-Volhard, 2015; Dooley, et al., 2013a; Budi, et 
al., 2011; Tryon, et al., 2011; Hultman, et al., 2009). MSCs are the source of a few late-stage 
embryonic melanocytes in the lateral stripe, adult stage melanocytes and regenerative 
melanocytes in embryos and adults (Iyengar, et al., 2015; Yang and Johnson, 2006; Budi, et al., 
2011; Hultman and Johnson, 2010). 
How zebrafish MSC activation is coupled with progenitor expansion and differentiation is not 
well understood. Erbb3 (EGFR) and Kit signaling pathways are required for MSC establishment 
at the dorsal root ganglia, and zebrafish embryos with erbb3 mutations or treated with ERB 
inhibitors during early development are depleted for MSCs, and are unable to regenerate 
sufficient melanocytes to pattern the embryonic or adult stripes (Dooley, et al., 2013a; Budi, et 
al., 2011; Johnson, et al., 2011; Hultman, et al., 2009). Following MSC establishment, the 
melanocyte master transcription factor (MITF; Mitfa in zebrafish) is essential for the proliferation 
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and differentiation of MSC derived melanocyte populations (Johnson, et al., 2011). Additional 
MSC populations may be present in the zebrafish embryo, including a recently described ERB-
dependent population associated with blood vessels and dependent on Endothelin factors 
(Camargo-Sosa, et al., 2019).  
Here, we used both chemical and genetic melanocyte ablation approaches to trigger a MSC-
mediated regenerative response and screened for small molecule suppressors or enhancers of 
differentiation during regeneration. We discovered that the phosphatase PRL3 inhibits 
premature progenitor expansion and differentiation of the MSC lineage, and that a PRL3 
inhibitor leads to an increased rate of pigmented cell regeneration. PRL3 is a member of the 
Phosphatase of Regenerating Liver (PRL) gene family (Zeng, et al., 1998), named because 
PRL1 was first identified in regenerating liver (Mohn, et al., 1991). PRL3 mRNA is expressed in 
development and somatic tissues, but PRL3 protein translation is tightly regulated and little 
PRL3 protein is present in somatic tissues (Thura, et al., 2016; Lin, et al., 2013; Maacha, et al., 
2013; Wang, et al., 2010). PRL3 endogenous function remains largely unknown.  
The PRLs are a unique class of protein tyrosine phosphatases (PTPs) with a broad spectrum of 
potential substrates (McParland, et al., 2011; Al-Aidaroos and Zeng, 2010). PRL3 has a well-
established role in cancer cell migration, is highly expressed in metastatic cancers and is a 
marker of poor prognosis (Wei, et al., 2018; Laurent, et al., 2011; Al-Aidaroos and Zeng, 2010; 
Bardelli, et al., 2003; Zeng, et al., 2003; Saha, et al., 2001). PRL3 is a p53 target gene and cell 
cycle regulator (Basak, et al., 2008), and has various targets (Chong, et al., 2019; Duciel, et al., 
2019; Zhang, et al., 2017; Lin, et al., 2013; Maacha, et al., 2013; Basak, et al., 2008). 
Supporting a role for the PRL family in regeneration, mutations in PRL2 lead to a depletion of 
hematopoietic stem cells in mouse (Kobayashi, et al., 2017; Kobayashi, et al., 2014). However, 
PRL3 has no previously known function in stem cell biology or regeneration. Here, we reveal an 
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endogenous function for PRL3 in transcriptional elongation in both MSC regeneration and in 
melanoma. 
Results 
A zebrafish small molecule screen uncovers B4-Rhodanine as a regulator of MSCs 
Whole genome sequencing has revealed that phosphatases are frequently mutated or lost in 
patients with melanoma (Hayward, et al., 2017). Therefore, to identify potential regulators of 
activated MSCs, we treated zebrafish embryos with a library of small molecule phosphatase 
inhibitors in the presence of NFN1. NFN1 is a 5-nitrofuran pro-drug that is activated by ALDH2 
to selectively kill cells expressing aldh2, including zebrafish melanocytes (Sarvi, et al., 2018; 
Zhou, et al., 2012), although the cell death mechanism (e.g. apoptosis) is not yet known in 
zebrafish. Embryonic melanocyte ablation triggers activation of a MSC regenerative program, 
enabling us to screen for regulators of the MSC (Figure 1A).  
We treated zebrafish embryos with the Enzo Life Sciences SCREEN-WELL Phosphatase library 
(33 phosphatase inhibitors) in the presence of our melano-cytotoxic compound NFN1 and 
followed melanocyte regeneration over time after washout (Figure 1A). None of the inhibitors 
prevented the melano-cytotoxic effects of NFN1 indicating that they did not interfere with NFN1 
activity in embryonic melanocytes. As expected, embryos treated with NFN1 and DMSO (a 
solvent control) were depleted of embryonic melanocytes at 50 hours post fertilization (hpf) and 
showed the initiation of melanocyte regeneration by 100 hpf (Figure 1B). By comparison, 
embryos treated with NFN1 and the compound B4-Rhodanine (B4-Rh) were also depleted of 
embryonic melanocytes at 50 hpf but showed dramatic melanocyte regeneration by 100 hpf 
(Figure 1B). Time-lapse imaging showed that melanocytes emerged de novo from within the 
tissue more quickly in B4-Rh treated embryos (Video S1). 
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Next, we used a second melanocyte regeneration assay based on a genetic temperature 
sensitive mutation in Mitfa, called mitfavc7 (Zeng, et al., 2015; Johnson, et al., 2011; Taylor, et 
al., 2011). These mutant zebrafish do not generate embryonic melanocytes at higher water 
temperatures because they lack Mitfa activity, and after 48-72 hours embryonic melanocyte 
precursors are considered to have died. However, they are able to establish ERB-dependent 
MSCs and generate melanocytes from the MSC lineage when Mitfa activity is restored at lower 
water temperatures (Johnson, et al., 2011). We found that B4-Rh treatment increased 
melanocyte regeneration at lower water temperatures in mitfavc7 zebrafish (Figure S1A, B). 
Thus, B4-Rh effectively enhanced melanocyte regeneration in both chemical and genetic 
regeneration assays suggesting B4-Rh is a bona fide regulator of the MSC lineage. 
B4-Rh induced the strongest regeneration phenotype in our screen with no effect on direct 
developing melanocytes (Figure 1C). Adult melanocyte regeneration is also dependent on 
MSCs established during development (Mort et al., 2015). We found B4-Rh increased 
melanocyte regeneration from an un-pigmented precursor in an adult tail fin regeneration assay 
(Rawls and Johnson 2000) (Figure S1C-E). This indicates that B4-Rh can regulate melanocyte 
regeneration from the MSC in both embryonic and adult zebrafish.  
B4-Rh is a highly reactive compound, which potently inhibits Phosphatase of Regenerating Liver 
3 (PRL3) (Ahn, et al., 2006). Molecular modeling and automated docking predicted that B4-Rh 
binds and inhibits the PRL3 phosphatase site in a hydrophobic pocket that is conserved in 
zebrafish (Figure 1D). Given the specificity of B4-Rh for the MSC lineage and the novelty of B4-
Rh and its target PRL3 in the stem cell response, we chose to focus on B4-Rh and PRL3 as 
novel regulators of the MSC lineage. 
Prl3a inhibits melanocyte regeneration from the MSC lineage 
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We hypothesized that Prl3 is targeted by B4-Rh in zebrafish, and is required in the activated 
melanocyte stem cell lineage during regeneration. To test this, we generated prl3 genetic loss-
of-function and over-expression mutants and assayed their phenotypes in regeneration.  
Zebrafish have two prl3 genes (prl3a and prl3b); Prl3a is the most similar to human at the 
protein level (87% vs 74% protein identity) (Figure S2A). Similar to the effects of B4-Rh, a 
TALEN prl3a mutant that we generated (as well as morpholino knockdown) had no overt 
embryonic melanocyte phenotype but had increased melanocyte regeneration in the mitfavc7 
background (Figure 1E, F; Figure S2B-E). B4-Rh treatment of the prl3a mutant did not further 
increase this phenotype, supporting the concept that B4-Rh is acting through Prl3a (Figure 
S2F). In contrast, a prl3b CRISPR mutant had no detectable embryonic or MSC melanocyte 
phenotype either on its own, or in addition to the prl3a mutant (Figure 1E, F; Figure S2D; data 
not shown) suggesting that Prl3b does not have unique functions in MSC differentiation. Thus, 
we focused our efforts on investigating prl3a in the MSC response.  
Next, we overexpressed prl3a mRNA in zebrafish embryos and found that this inhibited 
melanocyte development (Figure 1G). This phenotype was lost upon mutation of the catalytic 
cysteine to serine (C104S) (Figure 1G) indicating Prl3a phosphatase activity is required to 
inhibit melanocyte development. To overexpress prl3a throughout the embryo, we generated 
homozygous Tg(ß-actin:prl3a) transgenic zebrafish in the mitfavc7 background (Figure S2G). 
Ubiquitous overexpression of prl3a partially inhibited development of embryonic melanoblasts 
and, importantly, suppressed melanocyte regeneration from the stem cell lineage (Figure 1E, F; 
Figure S2H, I).  
Loss of Prl3 activity prematurely increases MSC-derived melanoblast populations 
To determine the developmental stage altered by B4-Rh, we treated mitfavc7 zebrafish embryos 
(primed to regenerate) with B4-Rh and found that it led to an increase in mitfa-expressing cells 
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(Figure 2A), but not of sox10 or foxd3-expressing cells (Figure 2B). These data indicate that 
B4-Rh-mediated inhibition of Prl3a activity impacts melanocyte progenitor (melanoblast) 
development from MSCs during regeneration, and not earlier in the neural crest lineage.  
Next, we used live-imaging to examine Tg(mitfa:GFP;nbt:dsRED) zebrafish embryos during 
melanocyte regeneration (Dooley, et al., 2013a) (Figure 2C, D). mitfa:GFP enables visualization 
of melanoblasts, whereas nbt:dsRED enables visualization of the neural tube and peripheral 
nerves, helping establish the location of the MSC niche (Dooley et al., 2013). DMSO or B4-Rh 
treatment had no effect on mitfa:GFP expression in non-regenerating zebrafish. However, NFN1 
treatment led to an increase in GFP+ cells at the MSC niche indicating a regeneration response. 
Strikingly, embryos treated with NFN1 and B4-Rh showed a strong increase in GFP+ cells in the 
MSC niche and along motor axons (Figure 2C, D). These data show that inhibiting Prl3a 
causes premature expansion of melanoblasts during regeneration from the MSCs and reveal an 
activity for Prl3 in a stem cell lineage.  
We wanted to understand if Prl3 functions before or after ERB signaling in the MSC lineage. 
Treatment of wild type embryos with the ERB inhibitor AG1478 leads to gaps in the embryonic 
melanocyte lateral stripe (Hultman and Johnson, 2010). This assay enables us to test B4-Rh 
activity on the MSCs in a non-regenerating context. We found that the PRL3 inhibitor rescued 
the loss of the melanocytes in the lateral stripe of AG1478 treated embryos (Figure 2E). Next, 
we tested the PRL3 inhibitor in the mitfavc7 regeneration assay with AG1478 (Figure 2F). ERB 
inhibitor treatment prevents melanocyte regeneration in the mitfavc7 regeneration assay, 
indicating that regeneration in the mitfavc7 mutant depends on ERB dependent MSCs (Johnson 
et al., 2011). Co-treatment of B4-Rh and AG1478 rescued the number of regenerating 
melanocytes in the mitfavc7 regeneration assay (Figure 2F). Together, these two independent 
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MSC assays provide evidence that PRL3 inhibition rescues the dependency on ERB-signaling, 
suggesting that PRL3 activity acts downstream of the ERB pathway in the MSC lineage. 
Prl3a interacts with the RNA helicase Ddx21 
To explore Prl3a targets during zebrafish melanoblast development we generated a Prl3a-GST 
fusion protein, isolated interacting partners from zebrafish cell extract, and performed mass 
spectrometry. One of the strongest interacting partners for Prl3a identified was the DEAD box 
protein and RNA helicase Ddx21 (Figure 3A, Table S1). DDX21 has emerged as a central 
regulator of Pol I-dependent ribosome biogenesis and of Pol II transcriptional elongation, and a 
sensor of nucleotide stress (Calo, et al., 2018; Calo, et al., 2015; Santoriello et al., 2020). 
Notably, we found that Prl3a bound many proteins involved in transcription control, including 
components of the acetyltransferase complexes, the mediator complex, RNA polymerase I and 
II, and the transcription elongation factor complex (Figure 3B).  
To address if the PRL3-DDX21 interaction was relevant to the MSC regeneration response, we 
injected zebrafish embryos with a ddx21 morpholino. As reported by others (Calo, et al., 2018), 
we found no effect on embryonic melanocytes after ddx21 knockdown. In contrast, we found 
ddx21 to be required for the MSC regeneration response (Figure 3C). Given the strong 
interaction between Prl3 and Ddx21 in zebrafish extracts coupled with the requirement for 
Ddx21 in melanocyte regeneration, we chose to pursue Ddx21 as a novel Prl3a interacting 
partner. 
To address if the zebrafish Prl3a-Ddx21 interaction is conserved in human cells, we generated 
A375 melanoma cells that stably express human PRL3 fused to HA. A375 cells express low 
levels of endogenous PRL3 (Figure S3A, B), and PRL3 over-expression had no discernible 
effect on growth or cell cycle stages (Figure S3C-E). We found that DDX21 co-
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immunoprecipitated with PRL3-HA (Figure 3D). To study the subcellular localization of the 
PRL3-DDX21 interaction, we performed structured illumination microscopy (SIM), a super-
resolution microscopy technique that enables resolution beyond conventional methods (Figure 
S3F). In cells that express high endogenous PRL3 (C092 melanoma cells), we found that PRL3 
and DDX21 co-localized as punctate clusters in the nucleoplasm (Figure 3E; Figure S3F, G). 
Further, we found these foci were greatly enriched in the nuclei of A375 melanoma 
overexpressing PRL3-HA (Figure 3F).  
DDX21 is predicted to be a highly phosphorylated protein, and phosphorylation may regulate 
DDX21 localization between the nucleus, nucleolus and cytoplasm (Calo, et al., 2018; Mialon, et 
al., 2008). Using mass spectrometry, we found phosphorylation of DDX21 at sites S71, S89 and 
S121 (Figure 3G). S71 phosphorylation was strongly reduced in A375 cells expressing PRL3-
HA, suggesting that PRL3 activity regulates DDX21 phosphorylation (Figure 3G, Table S2). To 
test if these sites had activity in vivo, we injected zebrafish embryos with DDX21 and 
DDX21(S71A) mRNA in the mitfavc7 regeneration assay and showed DDX21(S71A) selectively 
reduced regeneration in the prl3a mutant but not prl3a wild type embryos (Figure 3H). These 
data indicate that DDX21(S71A) functions in a dominant manner to rescue the prl3a mutant. 
Together, these data show that DDX21 de-phosphorylation is the primary function for Prl3a 
activity in melanocyte regeneration, and that S71 is a critical target residue on DDX21 for PRL3.  
PRL3 impairs transcriptional elongation of endolysosomal biogenesis genes 
DDX21 binds promoters of RNAPII genes to release paused polymerase and activate 
transcription elongation (Calo, et al., 2015). The presence of PRL3-DDX21 complexes in the 
nucleoplasm led us to hypothesize that PRL3 regulates transcriptional elongation via DDX21. 
To investigate this, we used metabolic labelling with 4-thiouridine RNA sequencing (4sU-seq) to 
label nascent RNA transcripts (Rabani, et al., 2011) in A375 cells that stably express either 
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PRL3 or an empty vector control (Figure 4A). Genome-wide analysis of read coverage 
normalized to gene length identified an accumulation of transcripts toward the 5' end and 
depletion of transcripts in the 3' end of PRL3-expressing cells, and this was most pronounced 
for long genes (>10 kb) (Figure 4B, C, Table S3).  
Visual inspection of individual genes supported this finding but also revealed that most of the 5’ 
accumulation reads arose from exons. Therefore, to ensure an analysis of nascent transcripts 
and to remove potential confounding effects arising from co-transcriptional splicing or low-level 
mRNA carry-over, we focused all subsequent analysis on the quantitation of intronic reads. We 
found 1745 genes that accumulated transcripts toward the 5’ end of the gene body ("5’ enriched 
genes") and 40 genes that accumulated transcripts at the 3’ end in PRL3-overexpressing 
melanoma cells relative to controls (Figure 4D; Table S3).  Over 62% of 5’ enriched genes 
(1121/1785) showed reduced mRNA levels in PRL3-expressing cells compared to control 
(Figure 4E; Table S3). Analysis of the 5’ enriched genes revealed a striking enrichment of 
genes and pathways involved in endolysosomal components including late 
endosome/lysosomal vesicle trafficking/tethering and vacuolar ATPases required to maintain an 
acidic pH (Figure 4E, F; Table S3). Melanosome and pigment granule cellular components 
were also enriched in our analysis, although the genes that constitute these pathways were not 
specific to melanosomes, rather they were shared with lysosomes and endomembrane vesicle 
genes because melanosomes are lysosome-related organelles (Bowman, et al., 2019; 
Wasmeier, et al., 2008). 
To determine if the PRL3-mediated repression of endolysosomal vesicle gene expression is 
associated with a change in cellular vesicles, we used Lysotracker Red to stain acidic vesicle 
compartments in live cells (Chazotte, 2011). Overexpression of PRL3 in human melanoma cells 
resulted in a decrease of lysotracker-positive vesicles as measured by the total area of 
fluorescence per cell (Figure 4G, H). Of the lysotracker-positive vesicles still present in PRL3 
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overexpressing cells, they were reduced for lysotracker fluorescence but with no change in size 
(Figure 4I; Figure S4A-C). These cellular phenotypes are reliant on the phosphatase activity of 
PRL3 because acidic vesicles were unchanged in cells overexpressing the phosphatase-dead 
PRL3C104S.  
PRL3 overexpression enriches DDX21 at the 5' end concomitant with reduced productive 
RNAPII transcription  
To investigate whether genes regulated by PRL3 are targeted by DDX21, we compared a 
DDX21 ChIP-Seq dataset from A375 melanoma cells (Santoriello et al., 2020) to our PRL3-
dependent 5’ enriched genes. We observed a significant enrichment overlap (60%; 1048/1745 
genes; p-value=7.63e-99) between genes regulated by PRL3 and between DDX21 targets. The 
cellular components of these genes notably involved endolysosomal vesicle biogenesis (Figure 
5A; Tables S3, S4).  
To investigate the relationship between PRL3 and DDX21, we performed DDX21 ChIP-seq in 
control and PRL3-overexpressing cells. PRL3 overexpression had little effect on DDX21 binding 
to chromatin overall, but significantly reduced DDX21 binding at PRL3-regulated 5’ enriched 
genes (Figure 5B), as well as other known RNAPII-associated DDX21 targets (Figure S5A). 
Moreover, in PRL3-overexpressing cells, the distribution of DDX21 binding at 5’ enriched genes 
accumulated at the 5' transcription start site (TSS) and depleted in the gene body and 3' 
transcription end site (TES) (Figure 5C).  
Next, we asked if the shift in DDX21 distribution at PRL3-regulated 5’ enriched genes correlated 
with alterations in RNAPII distribution and activity. To this end, we performed ChIP-seq for total 
RNAPII, as well as phospho-Ser5 RNAPII and phospho-Ser2 RNAPII. The phosphorylation of 
the Carboxy Terminal Domain (CTD) of RNAPII is dynamic across the length of transcribing 
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genes. Phospho-Ser5 RNAPII is associated with transcriptional initiation, and both phospho-
Ser5 and phospho-Ser2 phosphorylation are associated with elongation (Chen et al., 2018). We 
found that PRL3 overexpression resulted in reduced levels of both Ser5 and Ser2 forms of 
RNAPII at 5’ enriched genes (Figure 5D-F). These findings suggest that PRL3 impairs DDX21 
binding and distribution on chromatin, thereby reducing productive RNAPII transcription and 
leading to the accumulation of transcripts at the 5’ end of endomembrane vesicle genes. 
PRL3-DDX21 transcriptional regulation of MITF endolysosomal target genes  
Next, we wanted to understand how endolysosomal target genes were chosen by PRL3-
DDX21. MITF has an ancestral role in regulation of the V-ATPase genes, and a unique and 
selective role for regulation of genes involved in endolysosomal biogenesis (Moller, et al., 2019; 
Bouche, et al., 2016; Ploper, et al., 2015; Zhang, et al., 2015). To investigate whether MITF 
participates in the transcription of PRL3-DDX21-regulated genes, we performed ChIP-seq for 
total MITF using a validated antibody and confirmed the enrichment and specificity for known 
MITF targets (Webster et al., 2014; Figure S5B-D). We found an increase in MITF chromatin 
binding at the TSS of PRL3-regulated genes compared to all long genes (≥10 kb), with further 
enriched MITF binding at 5’ enriched genes in PRL3 expressing cells compared to the control 
(Figure 5G). Increased MITF binding at 5’ enriched genes in PRL3-expressing cells may 
indicate that MITF residency time is coupled to Pol II licensing and active elongation (Swift and 
Coruzzi, 2017). To examine these genes more closely, we performed peak-finding analysis on 
the MITF ChIP-seq data followed by GO Enrichment analysis for the PRL3-DDX21-MITF 
common target genes. We found 162 out of 1048 (15.5%) PRL3-DDX21 target genes (Figure 
5H, I; Table S3) had robust MITF binding peaks and were enriched in endolysosomal factors 
(Figure 5I). Thus, PRL3-DDX21 transcriptional regulation is active at MITF-dependent 
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endomembrane/lysosomal genes and represents a new regulatory mechanism of MITF 
controlled gene expression. 
Prl3a negatively regulates endolysosomal vesicle accumulation in zebrafish MSC 
differentiation 
Given our findings in human cells, we hypothesized that a transcriptional mechanism underlies 
Prl3a function in the zebrafish MSC lineage. We performed single-embryo RNA-seq on 
hemizygous transgenic Tg(ß-actin: prl3a) embryos (one copy of the transgene is not sufficient to 
prevent melanocyte development) and matched sibling controls (Figure 6A). We identified 
selective downregulation of transcripts that encode vesicle fusion, sorting, and melanosome 
maturation components, including almost all the components of the V-ATPase complex (Figure 
6B; Table S5). Next, we analyzed zebrafish 24 hpf single-cell RNA seq data (Wagner, et al., 
2018) and identified prl3a-expressing cells in neural crest and melanoblast populations (Figure 
6C). Gene-set enrichment analysis indicated that the prl3a+ subpopulation was significantly 
depleted for V-ATPase transcripts, whereas prl3a- cells were enriched for these transcripts 
(Figure 6D). This is consistent with our findings in mammalian cells and with a function for Prl3a 
in transcriptional inhibition of these genes. 
As prl3a- cells were characterized by increased gene expression of V-ATPase genes, we 
hypothesized V-ATPase inhibitors might restore enhanced MSC regeneration in prl3a-/- mutants. 
To test this, we treated prl3a-/- mutants with the V-ATPase inhibitor concanamycin A in a mitfavc7 
regeneration assay. Concanamycin A can lead to pigmentation defects at higher concentration 
because acidic vacuolar pH is required for melanosome formation (Dooley, et al., 2013b), but 
when we treated embryos at low concentrations (100 nM) of concanamycin A there was no 
effect on wild type melanocytes. Importantly, concanamycin A treatment during the activation of 
the MSC but prior to melanin synthesis reversed the regeneration phenotype in prl3a-/- mutant 
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embryos, indicating that acidic vesicles contribute to the enhanced rate of differentiation from 
the MSC lineage in prl3a-/- mutants (Figure 6E, F). We did not observe an effect on wild type 
regeneration possibly because the embryos already have low levels of endomembrane vesicles 
at this stage. These data functionally implicate V-ATPase activity in melanocyte regeneration in 
prl3a mutants. 
A PRL3-high endolysosomal-low transcriptional signature in melanoma patients 
PRL3 expression is upregulated in many cancer types and associated with increased 
metastasis and poor patient outcomes (Wei, et al., 2018; den Hollander, et al., 2016; Mollevi, et 
al., 2008), however, there is limited analysis of PRL3 and patient outcomes in non-uveal, 
cutaneous melanoma. We asked if this newly identified function for PRL3 in transcriptional 
regulation is evident in human melanoma samples. To this end, we analyzed gene expression 
patterns in the melanomas with the highest and lowest PRL3 expression from TCGA (369 
metastatic patients), Leeds (703 patients; primary, treatment naive tumors) and Lund (140 
patients; Stage III) cohorts (Cancer Genome Atlas, 2015; Cirenajwis, et al., 2015; Nsengimana, 
et al., 2015; Newton-Bishop, et al., 2009) (Figure 7A). Strikingly, depletion of endomembrane 
vesicle components was a hallmark of PRL3-high melanomas in all three patient cohorts 
(Figure 7B, C; Table S6). In contrast, we found stem cell state genes enriched in PRL3-high 
melanomas (Figure S6A).  
Next, to explore the impact of PRL3 expression on patient prognosis stratification in melanoma, 
we performed comprehensive survival analysis to assess all possible cut-points to assign 
patients to high or low PRL3 expressing groups (Pearce, 2017). Almost half (48.6%) of the 701 
possible cut-points for the 702 patients in the Leeds dataset significantly associated (p<0.05) 
high expression levels of PRL3 with melanoma-specific death (Figure 7D and Figure S6B). 
High PRL3 expression was also significantly associated with melanoma-specific death in the 
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smaller Lund dataset (Figure 7D and Figure S6C). Consistent with our functional studies, PRL3 
expression was inversely correlated with a number of endolysosomal component genes in the 
Leeds and Lund melanoma patient cohorts (Figure 7E).  
Notably, there was no significant association of PRL3 with disease stage (a known prognostic 
factor) indicating that high PRL3 expression is a valuable predictive marker for metastatic 
melanoma-specific death in all stages (Figure 7E, Figure S6D, E). This was further validated in 
a stage-matched sub-cohort of metastatic melanomas where high PRL3 expression was still 
associated with increased disease-specific death and low PRL3 expression with endolysosomal 
gene expression (Figure S6F-H). Thus, similar to our zebrafish and cell line models, PRL3 
expression is inversely associated with endolysosomal vesicle gene expression in clinical 
samples, suggesting PRL3-mediated transcriptional regulation of these genes functions in 
metastatic melanoma.  
Discussion 
Somatic stem cells couple self-renewal with differentiation during tissue repair and regeneration, 
and these pathways are often dysregulated in cancer. Here, we present the conceptual advance 
that regulation of transcription elongation prevents premature MSC differentiation and reveal a 
new mechanism that regulates endolysosomal target genes via PRL3-DDX21-mediated 
inhibition. Given that stemness is associated with metastasis in cancer, including melanoma 
(Rambow et al., 2019; Oskarsson et al., 2014), we propose that PRL3 function in the MSC 
lineage during regeneration may be linked to its role in metastasis. 
Transcription through gene bodies is subject to dynamic changes in elongation rate, and is a 
highly regulated process in development and differentiation (Chen, et al., 2018; Jonkers and Lis; 
2015; Bai, et al., 2010; Maslon, et al., 2019; Tan, et al., 2016; White, et al., 2011). We propose 
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PRL3-DDX21 regulation of productive transcription elongation functions as a fine-tuning 
mechanism for matching the regenerative response with tissue needs, and an opportunity for 
specifically targeting cancer cells in a non-regenerative setting. Phosphorylation of DDX21 is 
likely central to this mechanism, and our finding that the DDX21 S71A phospho-mutant reduces 
and restores the rate of regeneration in prl3a mutants, points to a function for dephosphorylated 
DDX21 in delaying transcription through endomembrane genes.   
While it might be supposed that PRL3 regulation of MSC differentiation is via melanosome 
synthesis, in fact, we do not identify PRL3 5’ enriched genes that are specific to the 
melanosome or to melanin synthesis. Rather, the endolysosomal genes regulated by PRL3 are 
associated with lysosomal related acidic organelle biosynthesis and trafficking. Notably, 
dysregulation of endolysosomal pathways has emerged as a hallmark of melanoma and a driver 
of metastasis (Alonso-Curbelo, et al., 2014; Marie et al., 2020). In melanocytes and melanoma, 
MITF is the transcriptional regulator of V-ATPase gene expression (Bouche, et al., 2016; Zhang, 
et al., 2015) and these genes are required for autophagosome formation in response to 
starvation (Moller, et al., 2019) and are also required for endolysosomal vesicles that function as 
concentrating centers for Wnt signalling (Ploper, et al., 2015). Thus, it seems likely that PRL3-
dependent restrained transcriptional elongation of endolysosomal components leads to more 
than simply delaying melanosome biogenesis, and points to a function in maintaining a stem cell 
state. Indeed, the dramatic increase of early-stage melanoblasts emerging from the MSC 
compartment in B4-Rh treated regenerating zebrafish embryos supports the concept that 
endomembrane vesicles function at an early stage of MSC-derived melanoblast development 
prior to pigmentation, and prior even to expression of functional Mitfa protein, as demonstrated 
in the mitfavc7 mutants. The function of these vesicles in MSC differentiation is not known but 
may involve regulation of signalling pathways, such as the Notch pathway that is regulated by 
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endomembrane vesicles and inhibits premature differentiation of the MSC in the hair follicle 
niche (Aubin-Houzelstein et al., 2008; Schnute et al., 2018).  
PRL3 is a validated drug target for many metastatic cancers (Wei, et al., 2018). A humanized 
antibody against PRL3 demonstrated therapeutic efficacy as monotherapy in pre-clinical models 
(Thura, et al., 2016; Thura et al., 2019) and is currently being tested in a Phase 1 clinical trial 
(ClinicalTrials.gov Identifier: NCT03191682). Importantly, we find that high PRL3 expression is 
an independent predictor of melanoma-specific death at all stages. Thus, all patients with PRL3-
high melanomas may be at risk of metastasis and death, and benefit from PRL3 targeted 
therapies. 
In conclusion, despite the demonstrated function for PRL3 in metastatic cancers, an 
endogenous function of PRL3 activity in development has remained elusive. Our work identifies 
PRL3 as a lineage-specific regulator of DDX21 transcription elongation at endolysosomal genes 
to prevent premature MSC differentiation during regeneration. The PRL3 transcriptional 
elongation mechanism we present here is a new example of MITF regulatory control and of a 
developmental process that is co-opted by melanoma to maintain a progenitor state.  
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Figure Legends: 
Figure 1. Prl3a is an inhibitor of melanocyte regeneration in zebrafish 
A. Schematic of a small-molecule screen for regulators of MSC-derived melanocytes in 
zebrafish. MSC: Melanocyte Stem Cell; NCC: Neural Crest Cells. 
B. Images of zebrafish embryos treated with NFN1 +/- DMSO or B4-Rh and after washout. 
C. Quantification of zebrafish melanocytes during normal development (n.s.: not significant, 
Student’s t-test), or in a NFN1-regeneration assay (ANOVA using Tukey’s analysis; * p-value 
=0.0131, **** p = <0.0001).  
D. Predicted binding of B4-Rh (yellow sticks) in the NMR model of PRL3 (grey transparent 
surface and secondary structure; red: helix, green: loop). Purple-dashed line: predicted 
hydrogen bond to E50. All other protein-ligand interactions are apolar. The ligand sits in a 
hydrophobic pocket formed by residues: V48, C49, W68, P69, A74, P75, P77, V80, A111, V113 
and the methylene groups of the side chain of Q145. These residues, and E50, are conserved 
in zebrafish Prl3a. 
E. Images and F. quantification of wild type, Tg(β-actin:prl3a) and prl3 double mutant (prl3a-/-; 
prl3b-/-) zebrafish in a mitfavc7 MSC regeneration assay (**<p<0.01, ****p< 0.0001, n.s.: not 
significant, ANOVA Tukey’s test). 
G. RNA overexpression of prl3a and prl3a C104S in zebrafish embryos (50 hpf). 
See also Figure S1 and S2. 
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Figure 2. Inhibition of Prl3 leads to premature melanoblast expansion during 
regeneration 
A. mitfa in situ hybridization of DMSO and B4-Rhodanine (B4-Rhod) treated mitfavc7 zebrafish. 
Red box: zoomed region. Arrows: mitfa+ melanoblasts. LS: Lateral Stripe. NT: neural tube. 
Percentage area covered by mitfa-positive staining per embryo quantified (**** p-value < 
0.0001, t = 4.670, df = 35, unpaired, two-tailed t-test).  Line and error bars, mean ±S.E.M. 
(DMSO, n=23; B4-Rh, n=14 embryos). 
B. sox10 (DMSO, n=21; B4-Rh, n=16) and foxd3 (DMSO, n=10; B4-Rh, n=10) RNA in 
situ hybridization of treated mitfavc7 zebrafish. 
C. Confocal imaging of the melanocyte stem cell lineage during treatments specified. 
Tg(mitfa:GFP) marks regenerating melanoblasts (green arrows). Tg(nbt:dsRED) marks neural 
tube and axons. n=3 zebrafish per condition. NT: Neural Tube, PN: Peripheral Nerves, LS: 
Lateral Stripe. Maximum projection. Stack height: 30µm. Scale bar: 20 μm.  
D. Quantification of area of GFP expression (pixels2) on individual peripheral nerves of 84 hpf 
Tg(mitfa:GFP, nbt:dsRED) zebrafish embryos, 12 hours post-washout treatment specified  B4-
Rhodanine: B4-Rhod. DMSO, NFN1 and combination, n =3 embryos, B4-Rhod control, n=2 
embryos.   Line and error bars, mean ±S.E.M.  ** p-value = 0.0039, **** p-value = <0.0001, 
ANOVA using Tukey’s analysis. 
E. Lateral stripe melanocytes following specified treatments. AG.: AG1478. B4-Rhod.: B4-
Rhodanine. Red arrows: missing melanocytes; faint melanocytes from opposite side of the body 
are also visible. Quantification of melanocytes on the lateral stripe of embryos at 96 hpf, * p-
value = 0.0364; *** p-value =0.0003 and 0.0006 for DMSO vs. AG. and AG. vs. AG. + B4-Rhod 
respectively, ANOVA using Tukey’s analysis.   
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F. Melanocyte regeneration in mitfavc7 mutant embryos following specified treatments. AG.: 
AG1478.  B4-Rhod./ B4-Rh: B4-Rhodanine. Quantification of dorsal stripe melanocytes per 
embryo 40 hours post washout and mitfa activation, ** p-value = 0.0013, 0.0023 for DMSO vs. 
B4-Rhod and B4-Rhod vs. AG + B4-Rhod respectively; **** p-value <0.0001, ANOVA using 
Tukey’s analysis.  
  
 23 
 
Figure 3. Prl3a interacts with Ddx21 in zebrafish and melanoma cell nuclei 
A. Experimental overview, and intensity quantification of Ddx21 peptides from Prl3a-GST pull 
downs. Error bars: S.E.M. See also Table S1. 
B. Cellular component GO-enrichment analysis of Prl3a interacting proteins identified by co-
immunoprecipitation and mass-spectrometry (adjusted p values: Benjamini-Hochberg test). 
C. Quantification of melanocytes in a mitfavc7 regeneration assay following control or ddx21 
morpholino injection, ****p <0.0001 Student's t-test. 
D. Co-immunoprecipitation of human HA-tagged PRL3 protein from A375 cells: empty vector 
(EV) and PRL3 expressing stable transfected cells. 
E. Structured Illumination Microscopy (SIM) of endogenous PRL3 (magenta) and DDX21 
(green) in C092 melanoma cells. Scale bar = 1 μm. Co-localization indicated (arrows); Zoomed 
image shows PRL3-DDX21 co-localization with line scan, and intensity plot profile of line scan 
showing signal overlap (yellow arrow). DAPI: blue. See also Figure S3. 
F. Quantification of PRL3-DDX21 complexes per nucleus identified by SIM in A375 melanoma 
cells expressing empty vector or HA-tagged PRL3 (***p <0.001, error bars: S.E.M., Student's t-
test). See also Figure S3. 
G. Mass spectrometry of DDX21 phosphorylation sites in EV control cells (n=5 samples) and 
cells expressing PRL3 (n=7 samples) (***p <0.001, n.s.: not significant, error bars: S.E.M., 
Student's t-test). See also Table S2. 
H. Quantification of regenerating melanocytes in wild type or prl3a mutant mitfavc7 embryos 
injected with mRNA encoding DDX21 or DDX21 S71A.  (**p < 0.01, ANOVA using Tukey‘s 
analysis) 
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Figure 4. PRL3 restrains transcriptional elongation of endomembrane vesicle genes.  
A. Schematic of 4sU protocol to detect nascent RNA transcripts.  
B. 4sU transcriptional profile for long genes in EV (empty vector) versus PRL3 over-expressing 
cells. TSS: transcription start site. TES: transcription end site. Arrows indicate accumulation of 
transcripts to the 5' end and loss of transcripts in the 3' end of PRL3-expressing cells 
C. 4sU RNA-Seq transcript coverage for ATP6V1C1 and ATP1A1 nascent transcripts. In control 
EV cells (black) most transcripts align with exons (black arrows), while transcripts in PRL3 
expressing cells (red) accumulate are enriched at the 5’ end of the gene (red arrows). 
D. 4sU transcriptional profile for 5’ enriched genes in control and PRL3 expressing cells. 
Accumulation of transcripts to the 5' end and a decrease at the 3’ end of the gene body (red 
arrows) in PRL3 expressing versus control cells. 
E. Volcano plot of differentially expressed genes in PRL3 versus EV control A375 cells by 
DESeq2-analysis using 4sU nascent RNA sequencing data. See also Table S3. 
F. Bubble plot of GO cellular components in the PRL3-induced 5’ enriched genes.  
Endomembrane vesicle components highlighted in red. 
G. A375 melanoma cells expressing empty vector (EV), PRL3 and PRL3 (C104S) stained with 
LysoTracker (red), and Hoechst (blue). Scale bars: 50 µm.  
H. Quantification of the area of lysotracker-positive vesicles per cell.  ANOVA using Tukey’s 
analysis, ** p-value = 0.0015; **** p-value < 0.0001.  Line and error bars, mean ±S.E.M. 
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I. Quantification of the proportional mean intensity of lysotracker-positive vesicles per cell. 
ANOVA using Tukey’s analysis, *** p-value = 0.0005; **** p-value < 0.0001.  Line and error 
bars, mean ±S.E.M. 
See also Figure S4. 
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Figure 5.  PRL3 restrains Pol II transcriptional elongation of DDX21 target genes at MITF 
targets. 
A. Venn diagram of overlapping genes between DDX21 ChIP targets (purple) and PRL3 5’-
enriched genes (blue). GO-enrichment analysis of cellular components (FDR <0.05). See also 
Table S4. 
B. DDX21 ChIP-seq data as log2 ratios of PRL3 vs. EV control read depth for all long and 5’ 
enriched genes, **p = 1.61X10-8, Wilcoxon signed-rank test. 
C. DDX21 ChIP-seq read profile for all long or 5’ enriched genes in control and PRL3 
expressing cells. In 5’ enriched genes, PRL3 causes a net accumulation of DDX21 to the 5' end 
(red arrows) versus control treated cells (black arrow). 
D. Boxplots of RNAP II (total, Ser2P, Ser5P) ChIP-seq data shown as ratios of PRL3 vs. control 
read depth for all long and 5’ enriched genes. (5’ enriched p-values = 0.83, 1.26x10-18 3.93x10-11 
for Total, Ser2P and Ser5P RNAP respectively; Wilcoxon signed-rank test). 
E. RNAP II (Ser2P) ChIP-seq profile for 5’ enriched genes in control and PRL3 expressing cells. 
RNAP II (Ser2P) signal is decreased at the 5' end (red arrow) and throughout the gene body 
versus control cells (black). 
F. 4sU RNA-Seq and RNA PolII (Ser2P) ChIP-seq transcript coverage for ATP5F1A, an 
example 5’ enriched gene. In EV cells (grey) 4sU transcripts align with exons (grey arrows). In 
PRL3 expressing cells (red) transcripts are enriched at the 5’ end (red arrows) and RNAP II 
(Ser2P) depleted over the gene body in versus EV control cells. 
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G. MITF ChIP-seq signal surrounding the TSS (1 kb) for non-5’ enriched (grey) and 5’ enriched 
(red) genes (p-values determined using paired and un-paired Wilcoxon rank sum tests for within 
and between gene set comparisons respectively). 
H. MITF ChIP-seq profile of ATP5V0D1, a 5’ enriched PRL3 target gene. Elevated MITF 
occupancy in PRL3 vs. control EV cells proximal to the TSS. 
I. Venn diagram of DDX21 ChIP targets (white, 6566 total), PRL3 5’-accumulated genes (pink, 
1745 total), and MITF ChIP targets (blue, 2908 total). 162 genes overlap the three groups, 
highlighted in yellow (p=6.67e-06, hypergeometric test). Table lists cellular component GO-
enrichment analysis of these 162 genes (FDR <0.05). See also Table S4. 
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Figure 6. prl3 mutants are rescued by a V-ATPase inhibitor 
A. Single embryo transcriptomics of heterozygote Tg(β-actin:prl3a) zebrafish reveals  atpv1aa, 
is selectively downregulated (adj. p-value <0.05) versus wild type control siblings. See also 
Table S5. 
B. g:Profiler output shows V-ATPase complex GO enrichment for Tg(β-actin:prl3a) differentially 
expressed genes versus wild type controls. Inset: diagram of V-type ATPase, all genes 
encoding components labelled red are downregulated in Tg(β-actin:prl3a) expressing embryos. 
C. K-nearest neighbor graph (SPRING webtool) of prl3a expression in neural crest lineages 
using Wagner et al., 2018 zebrafish 24 hpf single cell data. 
D. GSEA plotting enrichment of V-ATPase genes in the prl3a negative subpopulation of pigment 
cells from Wagner et al., 2018. 
E. Images and F. quantification of melanocytes in wild type or prl3a mutant embryo ± 
concanamycin A in a mitfavc7 regeneration assay, ANOVA Tukey’s test, **** p-value <0.0001. 
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Figure 7. A PRL3-high, endolysosomal gene-low signature in human melanoma samples  
A. Patient samples ranked by PRL3 RNA expression. PRL3-High and PRL3-Low subgroups 
were defined with a 10% threshold for TCGA (n=366) and Leeds (n=703) and 25% threshold for 
the Lund dataset (stage III patients, n=124).  
B. GO enrichment analysis (Cellular Compartment) of PRL3 subgroups in TCGA (Cytoscape). 
Node radius represents GO term gene counts. Spokes represent shared gene counts between 
terms.  
C. Bubble plot of GO cellular components in PRL3High versus PRL3Low melanomas. Over-
representation analysis (FDR <0.05). NES: Normalized Enrichment Score. 
D. Kaplan Meier survival curves of PRL3-high versus PRL3-low melanomas in the Leeds and 
Lund cohorts.  
E. Heatmap of endolysosomal genes ranked by PRL3 expression (mean-centred): high (red), 
low (blue). Melanoma deaths are indicated in black; stage is indicated by shades of grey, darker 
shades represent higher stage. Patient classification: PRL3-low (red), PRL3-high (green), as in 
D. 
See also Figure S6 and Table S6. 
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STAR Methods: 
KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Rabbit anti-DDX21 Abcam #ab182156 
IgG protein mag Sepharose beads Fisher Scientific #10249574 
Anti-HA-tag mAb-Magnetic Beads MBL # M180-11 
Rabbit anti-beta Tubulin Abcam #ab6046 
Mouse anti-DDX21 Santa Cruz #sc-376953 
Rabbit Anti-HA  Abcam #ab9110 
Mouse anti-PRL3 Santa Cruz #sc-130245 
IRDye 800 CW Donkey anti-rabbit IgG LICOR #926-32213 
IRDye 680 RD anti-mouse secondary LICOR #926-68072 
Chicken anti-rabbit conjugated Alexa Fluor 488 Invitrogen #A21441 
Goat anti-mouse conjugated Alexa Fluor 647 Invitrogen #A21236 
Rabbit anti-DDX21 (ChIP grade) Proteintech # 10528-1-AP 
Mouse anti-RNA-POLII (ChIP) Novus Biologicals # C15200004 
Mouse anti-RNA-POLII PS2 (ChIP) Novus Biologicals # C15200005-50 
Mouse anti-RNA-POLII PS5 (ChIP) Novus Biologicals #C15200007-50 
Rabbit anti-MITF (ChIP) Atlas Antibodies #HPA003259 
Protein G dynabeads ThermoFisher # 10003D; 1ml 
Chemicals, Peptides, and Recombinant Proteins 
NFN1 Maybridge #BTB05727 
Enzo Life-Sciences Screen-WellTM Phosphatase 
Inhibitor library 
Enzo Life-Sciences #BML-2834-0100 
B4-Rhodanine Sigma-Aldrich #P0108 (Sigma) 
4-thiouridine Sigma #T4509 
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Biotin-HPDP Pierce #21341 
Image-IT™ LIVE Lysosomal and Nuclear Labeling 
Kit 
ThermoFisher # I34202 
Sulforhodamine B sodium salt (SRB) Sigma-Aldrich #S1402 
Propidium iodide Roche #11348639001 
Concanamycin A (Folimycin) Abcam Ab144227 
AG1478 Calbiochem/Sigma-
Aldrich 
#658552 
Commercial Assays 
Tol2kit gateway cloning Kwan et al, 
DEVELOPMENTAL 
DYNAMICS 
236:3088–3099 
http://tol2kit.geneti
cs.utah.edu/index.
php/Main_Page 
mMESSAGE mMACHINE® T3 Kit Ambion Cat No: AM1348 
Low Input RiboMinusTM Eukaryote System v2 kit Ambion #A15027 
NEBNext Ultra Directional RNA library Prep kit for 
Illumina 
NEB #E7420S 
µMacs Streptavidin Kit Miltenyi #130-074-101 
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RESOURCE AVAILABILITY 
Lead Contact 
Further information and requests for reagents should be directed to and will be fulfilled by the 
Lead Contact, E. Elizabeth Patton (e.patton@igmm.ed.ac.uk). 
Materials Availability 
Newly generated materials from this study are available by request from the Lead Contact, E. 
Elizabeth Patton (e.patton@igmm.ed.ac.uk). 
Data and code availability 
4sU experiments have been submitted to GEO # GSE127855. Single-embryo transcriptomics 
data has been submitted to EMBL-EBI ENA # PRJEB12366. ChIP-seq data has been submitted 
to GEO # 1499299. All other data supporting the findings of this study are available from the 
corresponding author upon reasonable request. 
 
EXPERIMENTAL MODELS AND SUBJECT DETAILS 
Zebrafish husbandry 
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Zebrafish were maintained in accordance with UK Home Office regulations UK Animals 
(Scientific Procedures) Act 1986, amended in 2013, and European Directive 2010/63/EU under 
project license 70/8000 and P8F7F7E52, reviewed by the University of Edinburgh Animal 
Welfare and Ethical Review Body (AWERB). 
Human melanoma cell culture  
A375 cells (ATCC) were cultured in DMEM and C092 were cultured in RPMI (Life Technologies) 
media. Both media were supplemented with 2 mM L-glutamine (Life Technologies) and 10% 
fetal calf serum (Life Technologies) and all cells grown at 37°C in a 5% CO2 humidified 
incubator. A375 is derived from a female patient and C092 is derived from a male patient. C092 
has been authenticated through deep exome sequencing and short tandem repeat profiling. 
 
METHOD DETAILS 
Phenotypic screen 
Zebrafish wildtype embryos (AB, 4-5 hpf) were arrayed in a 24 multi-well plate (5 embryos/well). 
At 30 hpf embryos were treated with 20 μM NFN1 (Maybridge BTB05727) and co-treated with 
Enzo Life-Sciences Screen-WellTM Phosphatase Inhibitor library at 5, 10 and 20 μM 
concentrations. Embryos were assessed for NFN1 induced melanocyte ablation phenotype at 
50 hpf and drugs were washed out. Melanocyte regeneration was monitored daily following 
washout using a Nikon SMZ 1000 stereomicroscope. While B4-Rhodanine (PRL3 inhibitor) 
showed the strongest regeneration phenotype, a CDC25 inhibitor (BN-82002) also showed a 
mild enhanced regeneration phenotype, but the melanocytes were not fully pigmented 
suggesting additional activity for BN-82002 and/or CDC25 in pigmentation. 
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Melanocyte regeneration models and drug-treatment of zebrafish 
For NFN1 regeneration assays, wildtype (AB) embryos were treated with 20µM NFN1 ± 20µM 
B4-Rhodanine for 32-50 hpf. Following washout embryos were imaged and melanocytes 
counted at 100 hpf, n>3 experimental replicates. 
For B4-Rhodanine treatment in normal development, 4 hpf embryos were treated with B4-
Rhodanine or a DMSO solvent control. Drug treatment was replenished daily until embryos 
were imaged at 100 hpf, n>3 experimental replicates. 
For the genetic melanocyte regeneration assay, mitfavc7 embryos were grown at 32°C until 48 or 
72 hpf, followed by 48 or 72 hours at 25°C. Embryos were fixed between 100-120 hpf in 4% 
paraformaldehyde in PBS. Drug treatment of zebrafish embryos was performed from 4-5 hpf 
until 48 or 72 hpf as indicated. B4-Rhodanine was used at 20 μM or 10 μM (Sigma-Aldrich; 
Enzo Life Sciences), AG1478 was used at 6 µM (Calbiochem/ Sigma Aldrich) At 96 hpf embryos 
were imaged and counted, representative of 3 biological replicates. Concanamycin A (Abcam; 
100nM) was added to embryos from 8-72hpf before washing out during regeneration. 120hpf 
regenerated embryos were collected and fixed in 4% PFA in PBST and imaged using a Leica 
FLIII stereomicroscope.  
Adult tail fin regeneration assays were performed using a sterile razor blade to surgically 
remove a posterior portion of the tail in age-matched sibling fish. Tail-clipped adults were 
housed individually in control E3 medium or 1 µM B4-Rhodanine treatment groups. In some 
instances, fish were co-treated with 0.003% 1-phenyl-2-thiourea (PTU). 
For lateral stripe regeneration assays, wildtype zebrafish embryos were treated 0-48 hpf with 2 
µM or 6 µM AG1478 (Calbiochem/ Sigma Aldrich) and 20 µM B4-Rhodanine. Embryos were 
raised at 32°C. For a subset of experiments embryos were raised at 28°C and treatment was 
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continued from 48-96 hpf using 3 µM AG1478 and 10 µM B4-Rhodanine. At 96 hpf embryos 
were exposed to a bright light before imaging/counting to contract melanocytes. Representative 
of 3 biological replicates. 
Imaging Tg(mitfa:GFP; nbt:dsRED) transgenic zebrafish 
Embryos at 4 hpf Tg(mitfa:GFP;nbt:dsRED) were arrayed in 6-well plates (Corning) containing 
0.1% DMSO, 20 μM B4-Rhodanine (Sigma-Aldrich), 8 μM of NFN1 (Maybridge BTB05727) or 
both 20 μM B4-Rhodanine and 8 μM of NFN1 in 3 ml of E3 embryo medium. DMSO and B4-
Rhodanine treatments were performed between 4 and 48 hpf; NFN1 treatment was performed 
between 32 and 50 hpf. An alternate treatment regime included 0.1% DMSO, 20 μM B4-
Rhodanine, 20 μM of NFN1 or a combination of B4-Rhodanine and NFN1 from 30-70 hpf. 
Images of randomly picked embryos were acquired using a Leica SP5 confocal (Leica 
Microsystems) using LAS-AF software. Images were scanned using a HCX PL Fluotar 20X/0.5 
objective and zoom = 5. Data were analyzed using Fiji 1.0 and 64bit Java8. Representative of 3 
biological repeats. 
Whole mount in situ hybridization 
B4-Rhodanine treated (20 μM) mitfavc7 embryos grown at 32°C for 48 hours were fixed in 4% 
paraformaldehyde and dehydrated in 100% methanol until processed. The whole mount in situ 
hybridization protocol used was adapted from https://wiki.zfin.org/display/prot/Whole-
Mount+In+Situ+Hybridization. Riboprobes for mitfa, sox10 and foxd3 were kindly provided by 
R.N. Kelsh (University of Bath, UK). Representative of 2 biological replicates. 
In Silico Modelling of PRL3 with B4-Rhodanine 
Water molecules and other heteroatoms were removed from the NMR structure of human PRL3 
(PDB 1V3A) and the program PDB2PQR 2.1.1 used to assigned position-optimized hydrogen 
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atoms, utilizing the additional PropKa algorithm with a pH of 7.4 to predict protonation states. 
The MGLTools 1.5.6 utility prepare_receptor4.py was used to assign Gasteiger charges to 
atoms. Hydrogen atoms were assigned to compound structures using OpenBabel 2.4.1, utilizing 
the -p option to predict the protonation states of functional groups at pH 7.4. The MGLTools 
utility prepare_ligand4.py was used to assign Gasteiger charges and rotatable bonds. Autodock 
4.2.6 was used to automatically dock the compounds into the phosphate-binding pocket of the 
crystal structure. A grid box that encompassed the maximum dimensions of the cognate ligand 
plus 12 Å in each direction was used. The starting translation and orientation of the ligand and 
the torsion angles of all rotatable bonds were set to random. The Autogrid grid point spacing 
was set at 0.2 Å. The Autodock parameter file specified 50 Lamarckian genetic algorithm runs, 
7,625,700 energy evaluations and a population size of 300. The lowest energy conformation of 
the most populous cluster was predicted to bind with a Ki of 878 nM (± 2.5 kcal/mol). 
Generation of zebrafish transgenic and mutant lines 
Tg(ß-actin:prl3a) transgenics were generated by first cloning zebrafish prl3a cDNA, amplified 
from wild type zebrafish total RNA, using RT-PCR with primer sequence; forward: 5’-
GGGGACAAGTTTGTACAAAAAAGCAGGCTATGGCTCGCATGAACCGACC-3’ and reverse:5’-
GGGGACCACTTTGTACAAGAAAGCTGGGTTCACATGATACAGCACTTGTTC-3’. 
The ß-actin:prl3a targeting vector was generated using the Tol2kit gateway cloning method 
38.The prl3a PCR product was cloned into pDONOR221, producing a middle entry vector, 
pMEprl3a.pME-prl3a was cloned with the zebrafish actin promoter from p5E-actin2 (Tol2kit 
v1.2,plasmid #:299), and the SV40 polyA sequence from p3E-polyA into the pDestTol2CG2 
destination vector. 
The Tg(ß-actin:prl3a) targeting vector was mixed with Tol2 mRNA and microinjected into 1-cell 
stage wild type embryos, at a final concentration 25 ng/μl and 35 ng/μl respectively. Zebrafish 
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embryos expressing green fluorescent protein (GFP) transgenic marker in cardiac tissue were 
selected and grown to adulthood before crossing with wildtype zebrafish to obtain the F1 
generation with cardiac GFP expression. The prl3a mutant line was generated using TALEN 
nucleases. prl3a exon 7 (ENSDARG00000039997) was targeted with a TALEN pair that were 
kindly provided by Keith Joung (Addgene, plasmid # 35992 and 35993). The target sequence 
used was; TCTCCTGAAAAGGCGCTTcatcgaggagcccggcTGCTGCGTGGCTGTGCA. The 
TALEN binding site is written in upper case, and spacer sequence in lower case. A 273 bp 
sequence surrounding the target site was amplified using the following primers; forward: 5’-
CTATGGCAGTCGATTGCTTTGG-3' and reverse: 5’-CTAAGTACTAAGTGGTTGGTCG-3’. A F1 
fish carrying a mutation of 20 bp deletion (GAGGAGCCCGGCTGCTGCGT) at the target site 
was selected and named prl3a20 for further studies. The prl3b14 mutant line was generated 
using CRISPR/Cas9 technology. A guide RNA (gRNA) target was identified in exon 4 at the 
prl3b locus (ENSDARG00000054814) using the webbased ZiFiT targeter software 
(http://zifit.partners.org/). The target sequence was 5’- GGTGGCTGTGGCTCTTATAGagg-3’ 
(PAM sequence in lower case). Guide RNA expression vectors were constructed by in vitro 
synthesis of gRNA and Cas9 mRNA. The gRNA vector, DR274 and Cas9 mRNA expression 
vector, MLM3613 were kindly provided by Keith Joung (Addgene plasmid # 42250 and 42251). 
Screening identified the founder prl3bD14, which contained a 14 bp deletion (5’- 
TGGCTCTTATAGAG-3’) at the target site. 
Zebrafish morpholino oligonucleotides and RNA injections 
For the prl3 morpholino, 11ng fluorescein-labeled morpholino oligonucleotide was injected (5’- 
ATAGTTGTGCTTCCTTCCGACTCAA-3’ or 5’-GACCGTTCAACCAGGCCATACTGGA-3’) 
(Gene Tools, LLC) as well as the random control. This morpholino blocked expression of prl3a 
and prl3b. Regenerating melanocytes in prl3 morpholino-injected and control-injected fish were 
tested in the mitfavc7 regeneration assays with embryos raised at 32°C until 54 hpf before down-
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shifting embryos to 25°C and quantification and imaging of regenerating melanocytes at 96 hpf. 
Representative of 3 biological replicates. 
Embryos were injected at the one-cell stage with a 2.5 ng fluorescein-labeled morpholino 
against ddx21; (5’-ATTCTGGGAGACTCTTTCACGGCAT-3’) and fluorescein scrambled control 
morpholino (5’ATTgTcGGAAcACTgTTTcACGGCAT-3’) (Gene Tools, LLC). Regenerating 
melanocytes in ddx21 morpholino-injected and control-injected fish were tested in the mitfavc7 
regeneration assays with embryos raised at 32°C until 72 hpf before down-shifting embryos to 
25°C and quantification and imaging of regenerating melanocytes at 100 hpf. Representative of 
3 biological replicates. 
The prl3a RNA expression plasmids were constructed by gateway cloning. The prl3a 
phosphatase mutant C104S was generated from the middle entry vector pME-prl3a with a pair 
of mutagenesis primers: Forward CGTGGCTGTGCACTCCGTGGCCGGTTTAGGAAGAGC, 
Reverse GCTCTTCCTAAACCGGCCACGGAGTGCACAGCCACG. Both pME-prl3a and 
pMEprl3a C104S were assembled with the destination vector pSPE3-HA-RfA by performing a 
single-site LR reaction. The resultant vector pSPE3-prl3a and pSPE3-prl3a C104S were 
linearized with SfiI (NEB) and used as template for in vitro synthesis of wildtype and mutant 
prl3a mRNA. All mRNA was transcribed with mMESSAGE mMACHINE® T3 Kit (Ambion). To 
overexpress prl3a mRNA, 2 nl of mRNA (300 ng/μl) was injected into each 1-cell-stage 
embryos. 
Wild type human DDX21 was cloned into pCS2 at the BAMHI/Xho restriction enzyme sites. 
S71A was generated by direct mutagenesis using the Q5 Site-Directed Mutagenesis kit, 
following manufacturer’s instructions. DDX21 and DDX21(S71A) mRNA (200 pg) were injected 
into 1-cell-stage mitfavc7 embryos, maintained at 32ºC for three days, and shifted to room 
temperature, at which time the embryos were photographed for melanocyte count analysis. 
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Zebrafish embryos were dose sensitive to DDX21 or the phospho-site mutant DDX21 S71A 
such that higher concentrations lead to developmental delay and toxicity. However, lower doses 
were well tolerated. Representative of 3 biological replicates. 
Mass Spectrometry 
N-terminus tagged GST-Prl3a recombinant protein was expressed, purified and resuspended in 
20 mM Imidazole NP40 lysis buffer (Thermofisher) and sonicated for five seconds. The samples 
were pre-cleared using sepharose beads (Sigma), centrifuged multiple times and then mixed 
with Dynabeads (ThermoFisher). Zebrafish embryos were lysed in RIPA buffer (Sigma) 
containing cOmplete ULTRA and PhosSTOP tablets (Roche) and ground for 2 minutes using an 
automatic motor pestle. The samples were centrifuged, and supernatant transferred into a new 
tube. The GST-Prl3a WT and Prl3aC104S bound proteins were incubated with zebrafish 
embryo lysate for 2 hours. GST-Prl3 pulldowns were digested, analyzed and quantified as 
previously described 39. Endogenous DDX21 was immunoprecipitated from 500 μl human A375 
cell lysates using rabbit anti-DDX21 antibody (Abcam), which was added to the total cell lysate. 
The protein antibodies-IgG protein agarose beads (GE Healthcare) were used. The 
immunoprecipitated protein were on-bead digested with trypsin on a KingFisher Duo robotic 
workstation. Peptides were analyzed on a Lumos Fusion mass spectrometer with a 1s cycle-
time, 120K resolution in MS and HCD-MS/MS in the ion trap. Raw files were processed and 
analyzed by MaxQuant. DDX21 phosphorylation sites were quantified by normalizing the 
peptide intensity over DDX21 intensity. 0-values were set to not-a-number (NaN) if the peptide 
was identified in one of the replicates or set to 0 if not detected. Data table represents the 
median intensity, error bars are S.E.M., Students t-test, N was 6 for empty vector control, EV 
and 10 for PRL3HA overexpression. 
PRL3 stable transfection 
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HA-tagged PRL3 (Addgene) and PRL3-C104S plasmids were linearized and transfected with 
Attractene transfection reagent according to manufacturer's instructions (Qiagen). Targeted 
A375 cells were maintained in hygromycin containing media at concentration of 100 μg/ml. 
PRL3HA-C104S was generated by site-directed mutagenesis of wild type PRL3 in pCEP4-PRL3 
plasmid with the following primers sequences; forward: 5’-
GCGTGGCTGTGCACTCCGTGGCGG-3’ reverse: 5’- CCGCCACGGAGTGCACAGCCACGC-
3’. 
Co-IP and Western blotting 
Empty vector and PRL3HA cultured A375 cells were washed in ice cold PBS and lysed in RIPA 
buffer (Sigma) supplemented with cOmplete ULTRA and PhosSTOP tablets (Roche). The lysate 
was centrifuged at high speed to remove cell debris and the supernatant transferred into a new 
tube. Protein concentration was measured using Pierceprotein detection kit (Pierce) and 
measured on a Nanodrop. For PRL3 protein, pull-down anti-HA-tag mouse monoclonal 
magnetic agarose beads (MBL) were used. Membranes were blocked with 2% BSA (Sigma) 
and incubated with rabbit anti-beta Tubulin (Abcam), rabbit anti-DDX21 (Abcam), mouse anti-
DDX21(Santa Cruz), rabbit anti-HA (Abcam), mouse anti-PRL3 (Santa Cruz) and 1:1000 rabbit 
anti-PRL3 (Abcam) antibodies. The primary antibodies were detected with either anti-rabbit or 
anti-mouse LICOR fluorescent antibodies (LICOR) and scanned using the Odyssey imaging 
instrumentation. 
Fluorescent immunostaining and Lysotracker 
C092 cells were kindly provided by Professor Nick Hayward and the ABN Cell Line Bank (QIMR 
Berghofer Medical Research Institute). Cells were cultured on high precision cover-glass (Zeiss, 
Germany) in 6-well plates and fixed in 4% paraformaldehyde for 5 minutes at room temperature. 
Fixed cells were washed three times for 5 minutes in TBST and blocked in 3% BSA in TBST for 
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1 hour. Fixed cells were incubated with primary antibodies, rabbit anti-DDX21 (Abcam) and 
mouse anti-PRL3 (Santa Cruz), overnight at 4°C. The next day, the cells were washed three 
times in PBS and incubated with anti-rabbit conjugated Alexa Fluor 488 and anti-mouse 
conjugated Alexa Fluor 647 antibodies (Invitrogen). Fixed cells were washed, nuclear stained 
with DAPI (Sigma) and mounted in Vectashield® mounting media. 
Super-resolution images were acquired using Structured illumination microscopy. 3D SIM 
images were acquired on a N-SIM (Nikon Instruments) using a 100x 1.49NA lens and refractive 
index matched immersion oil (Nikon Instruments). Samples were imaged using a Nikon Plan 
Apo TIRF objective (NA 1.49, oil immersion) and an Andor DU-897X-5254 camera using 405, 
488 and 640nm laser lines. Z-step size for Z stacks was set to 0.120 μm as recommended by 
manufacturer's software. For each focal plane, 15 images (5 phases, 3 angles) were captured 
with the NIS-Elements software. SIM image processing, reconstruction and analysis were 
carried out using the N-SIM module of the NIS-Element Advanced Research software. Settings 
for acquisition and reconstruction were identical in all images. 
Cells expressing empty vector, PRL3HA and PRL3C104S were cultured in glass plates (In Vitro 
Scientific). The cells were stained with Lysotracker Red (ThermoFisher) for an hour in phenol 
red free media. Images of the cells were captured with a Leica SP5 confocal (Leica 
Microsystems) using the LAS-AF software.  Representative of 2 biological replicates. 
Cell cycle analysis 
Empty vector and PRL3HA cells were harvested and washed in PBS-buffer before being fixed in 
cold 70% ethanol for 30 minutes. Cells were centrifuged and washed twice in PBS-buffer. To 
ensure that only DNA was stained, the cells were treated with 5 µg/ml RNAse A and stained 
with 10 µg/mol Propidium Iodine solution (Roche). The samples were analysed on a LSR-
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Fortessa (BD Biosciences UK) and cell cycle graphs were generated using the FlowJoTM 
software. 
 
SRB-assay 
Growth curves for empty vector and PRL3HA cells were determined by using the 
sulforhodamine-B (SRB) assay (Sigma-Aldrich). 2000 cells per well was plated in 96-well plates 
and fixed at day 1, 2 and 3 post plating in 10% trichloroacetic acid for 1 hour at room 
temperature. The cells were then stained with 0.4% SRB for 30 minutes at room temperature. 
Plates were washed and analysed by dissolving the SRB stained cells in 10mM Tris-buffer and 
the absorbance measured at 564 nm. 
 
4sU RNA labelling, cDNA library generation and sequencing 
A375 cells stably expressing empty vector or PRL3HA at 80% confluency were treated with 500 
μM 4-thiouridine (Sigma) and incubated for 20 min at 37°C in a 5% CO2 humidified incubator. 
After 20 minutes, the media was removed, and the cells were immediately lysed using Trizol ™ 
(Invitrogen). The samples were incubated for 5 minutes at room temperature to allow 
nucleoprotein complexes to dissolve. After Trizol incubation, chloroform was added, and the 
samples were vigorously shaken for 15 seconds by hand followed by incubation at room 
temperature for 2-3 minutes. Samples were then centrifuged at 13,000 rpm for 15 minutes at 
4C and the upper aqueous layer transferred to a new tube. RNA was precipitated with 
isopropanol. Samples were vortexed briefly and incubated for 10 min at room temperature 
before centrifugation. The supernatant was removed, and samples were washed with 80% 
ethanol, vortexed briefly and centrifuged at 13,000 rpm for 10 minutes at 4°C. RNA was 
resuspended in water and dissolved by heating the RNA samples at 40°C for 10 minutes. Any 
potential contaminating DNA was removed by using a TURBO DNA-free kit (Ambion) following 
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manufacturer’s instructions. RNA was then transferred to a QIAshredder column and 
centrifuged for 1 minute. Flow through, containing RNA, was transferred to a fresh tube and 
RNA concentration determined. Roughly 100 μg RNA per sample was biotin labeled using 
biotin-HPDP (1 μg per sample) (Pierce) in biotinylation buffer (100 mM Tris pH 7.5, 10mM 
EDTA) and incubated for 1.5 h at room temperature with movement. Unincorporated biotin-
HPDP was removed by transfer to a Phase Lock Gel heavy tubes (Eppendorf) and washed with 
an equal volume of chloroform. Samples were incubated for 2-4 minutes and centrifuged for 5 
min at 4°C. The upper phase was transferred into new Phase Lock Gel heavy tubes and the 
chloroform step repeated. Samples were transferred into new tubes and RNA was precipitated 
by adding 1/10 volume of 5M NaCl and equal volume of isopropanol. Tubes were inverted to 
mix and incubated at room temperature for 10 minutes and centrifuged for 20 min at room 
temperature. The RNA was washed in 80% ethanol and resuspended in water. To clean the 
biotinylated RNA, biotinylated 4sU labeled RNA was mixed with streptavidin beads and 
incubated for 15 minutes at room temperature. The μMACS columns (Miltenyi) were equilibrated 
prior to use. The columns were placed on a magnetic stand and washed with washing buffer 
(100 mM Tris pH 7.4, 10 mM EDTA, 1M NaCl and 0.1% Tween 20) at room temperature. 
Freshly prepared elution buffer (100mM DTT) and RNA-bead mix was added to the μMacs 
columns and the flow though was discarded. Columns were washed with 65°C pre-heated 
washing buffer 3 times and then 3 times with room temperature washing buffer. RNA was eluted 
from the columns using elution buffer containing 100 mM DTT. Flow-through was collected in a 
tube containing RLT buffer (RNeasy MinElute Cleanup kit). The RNA flow-though was 
precipitated with 100% ethanol. Samples were cleaned up using RNAeasy MinElute Spin 
Columns according to manufacturer’s instructions. The RNA was cleaned from contaminating 
cytoplasmic and mitochondrial ribosomal RNA by using a Low Input RiboMinusTM Eukaryote 
System v2 kit (Ambion), following manufacturer’s instructions. The ribosomic RNA-depleted 
RNA was quantified using Qubit®3.0 fluorometer and Qubit RNA HS Assay kit (Thermo). cDNA 
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libraries were prepared using NEBNext Ultra Directional RNA library Prep kit for Illumina (NEB) 
following manufacturer’s instructions. NEBNext® Multiplex Oligos for Illumina® NEBNext® 
Multiplex Oligos for Illumina® (Index Primers Set 1) were used to barcode the RNA replicates. 
Barcoded cDNA libraries were mixed together and sequenced by Edinburgh Genomics 
(University of Edinburgh) using HiSeq 4000 150PE to yield at least 290M + 290M reads per 
lane. 
RNAseq pipeline 
Raw FASTQ sequence reads were quality checked using FastQC (v. 0.11.3) and aligned to the 
human genome (GrCh38) assembly using STAR (v. STAR_2.5.1b) software using the default 
parameters. The quality of the resulting alignment to the transcriptome (Ensembl annotation 
version GRCh38.91) was also checked using RNASeqQC (v. 1.1.8.1). Raw counts of reads 
covering the transcriptome (Ensembl annotation version GRCh38.91) were obtained using 
htseq-count (0.6.1) with the “-s reverse” option. Differential expression was analyzed using the 
Deseq2 R package (v. 1.20.0). 
Genome wide elongation estimate 
For exonic regions, the RNAQC geneBody_coverage.py script (v. 2.6.4) was used with BAM 
alignment files and genome annotation in bed format (Ensembl annotation version GRCh38.79, 
downloaded from the RNAQC website) to obtain a genome wide profile graph (or a subset of 
genes longer than 25kb and with more than 20 exons “long genes”, or a subset of genes smaller 
than 2kb “short genes”). Elongation estimate calculation per gene Intronic regions were used for 
this analysis. Reads were counted on the first and 4th quarter of the gene length. To prepare 
and select the intronic regions, all exons positions were downloaded from Ensembl. These were 
merged using bedtools (v. v2.26.0) to create one set of pseudo-exons per gene and the 
corresponding pseudo-introns positions. Overlapping genes were removed from the analysis, 
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including non-coding transcripts and small RNAs. The intronic positions were extracted from the 
corresponding first and fourth quartile of each gene. FeatureCounts (from the subread package, 
v. 1.6.1) was used to count reads over the positions and we normalized the raw counts with the 
size of the intronic regions used for respective gene. The ratio calculation was generated by 
removing zero counts, which may be due to genuine low expression, questionable gene model 
or unused isoforms and lack of intronic sequence in the respective quarter. The 5’ normalized 
intronic counts were divided by the normalized 3’ intronic counts. The ratios produced were 
statistically analyzed by simple independent two group Student’s t-test for 3 replicates. 
(https://stat.ethz.ch/R-manual/Rdevel/ library/stats/html/t.test.html Welch Two Sample t-test, 
two.sided). FDR was calculated by multiple comparison correction using BH methods. 
(https://stat.ethz.ch/R-manual/Rdevel/ library/stats/html/p.adjust.html). 
Whole-Cell ChIP of A375 cells 
Empty vector and PRL3 stable overexpressing cells were cultured to 80% confluency and 
harvested by dissociation with trypsin in PBS/EDTA. Cells were resuspended in PBS and 
immediately fixed in 1% formaldehyde in PBS for 10 minutes at room temperature. The fixation 
was neutralised by the addition of glycine and incubated for an additional 5 minutes. The cells 
were washed in cold PBS. Cell pellets were resuspended in 150 µl cold lysis buffer (1% SDS, 
10mM EDTA, 50 mM Tris-HCl pH8.1, 1x protease inhibitor cocktail, 1x PhosSTOP phosphatase 
inhibitors (Roche) and fresh 1mM DTT) and supplemented with 1350 µl 1% Triton X IP dilution 
buffer (1% Triton X, 20mM Tris-HCl pH8.1, 150mM NaCl, 2mM EDTA, 1x protease inhibitor 
cocktail (Roche), 1x PhosSTOP phosphatase inhibitors (Roche) and fresh 1mM DTT and 1mM 
PMSF) and incubated on ice for 10 min. 
Lysed cells were sonicated on ice for 5x30 seconds with a probe sonicator followed by 50-60 
cycles (30 sec on / 30 sec off) in a chilled bioruptor (Diagenode) to yield chromatin fragments 
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ranging between 200 – 800 bp in length. For MITF ChIP, lysed cells were sonicated in a chilled 
SoniPrep150 probe sonicator for 15x30 seconds with a 30 seconds gap between burst. Sheared 
chromatin was centrifuged at max speed for 10 minutes at 4C and the soluble supernatant 
transferred to new tubes. 500 l chromatin samples were supplemented with 5 l (5mg/ml) BSA. 
10% of the input was stored and the rest was used for the immunoprecipitation. Anti-DDX21 
(Proteintech; cat no. 10528-1-AP), RNA-POLII tot, RNA-POLII PS2, PS5 (Novus Biologicals) 
and MITF (Atlas Antibodies) were pre-bound to proteinG dynabeads (ThermoFisher) in 10% w/v 
BSA in PBS according to the manufacturer’s instructions (Life Technologies) for approximately 1 
h at 4C with rotation following which free antibody was removed with 3 washes of cold 10% w/v 
BSA in PBS. Chromatin and proteinG beads were combined and incubated over night at 4C (at 
a ratio of 500 ng of bead bound antibody per 1M cell equivalents of chromatin). Samples were 
washes at 4C with rotation through the following series: 2 times in 1% Triton X IP dilution 
buffer, 2 times with ChIP wash A (50mM HEPES ph7.9, 500mM NaCl, 1mM EDTA, 1% Triton X-
100, 0.1% Na-deoxycholate, 0.1% SDS. 1x protease inhibitor cocktail, 1x PhosSTOP 
phosphatase inhibitors (Roche) and fresh 1mM DTT) and 2 times with ChIP wash B (20mM Tris 
pH 8.0, 1mM EDTA, 250mM LiCl, 1% NP-40, 0.1% Na-deoxycholate, 1x protease inhibitor 
cocktail, 1x PhosSTOP phosphatase inhibitors (Roche) and fresh 1mM DTT). Finally, the 
samples were washed with TE (1mM EDTA ,10mM Tris pH8.0). The samples were 
resuspended in TE and supplemented with preheated 37C Extraction buffer (0.1M NaHCO3 
and 1%SDS), vortexed and incubated for 15 minutes at 37C on a vibrating platform. 
The pH of the extracted chromatin was adjusted by adding 6l 2M Tris-HCl pH6.8 following 
which both the ChIP and input samples were incubated with 20g RNAseA at 65C for 1 hour. 
Cross-links were reversed and the protein degraded by the addition of 20g Proteinase K and 
incubation at 65C for 6-8 h. Following removal of the dynabeads from the ChIP samples, DNA 
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was purified using a Qiagen PCR cleanup kit following manufacturer’s instructions. DNA 
libraries were prepared using NEBNext® Ultra™ II DNA Library Prep Kit for Illumina® kit and 
NEBNext® Multiplex Oligos for Illumina® NEBNext® Multiplex Oligos for Illumina® (Index 
Primers Set 1) following manufacturer’s instructions.  
MITF ChIP qPCR 
ChIP-MITF DNA and input were used for qPCR using Sybr Green master Mix (Roche) with 
added primers for MLNA (for 5’-TGG GTT CTT CCA ATG TGT CA-3’; rev 5’-TTT ATG CAT 
GGT CAC GTG GT-3’), ATPG6V1G1 (for 5’-TCC TCT CTT GAC GTT GAG CA-3’; rev 5’-CTA 
CCC TGT CGC TGG TTC AC-3’), ATPG6V1E1 (for 5’-GTA AAG GAA CCC GAG ATC TGC-3’; 
rev 5’-CAA TGC TAG GCC GGT GAA C-3’), FAM129A (for 5’-CCT CTT GCC TCC TGT CTC 
TC-3’; rev 5’-CTT GCC CTC GTC CAG CTG-3’), negative controls ACTB (for 5’-CTG GGT TTT 
ATA GGG CGC CG-3’; rev 5’-GCC GTT CCG AAA GTT GCC TT-3’) and ACTB intergenic 
region (for 5’-CCA CAA AAG ACT GAA GAC ACG G-3’; rev 5’-ACT TGT TCC TGT GCA CTA 
TGG T-3’). Samples were run on a Lightcycler480.  
ChIP-seq Mapping and Analysis 
ChIP-seq data was mapped to the human genome (GRCh38 build) using bowtie2 with default 
options for single end sequencing to generate SAM files. Using the HOMER package, SAM files 
were converted into tag directories and multi-mapping reads were removed using 
makeTagDirectory -unique -fragLength 150. Mapped regions, that due to fragment processing, 
extended beyond the end of the chromosomes were removed using 
removeOutOfBoundsReads.pl with chromosome lengths for GRCh38.  Replicate data, was 
combined at this stage and genome browser files (.bw) were generated using makeUCSCfile 
with the following options: -bigWig -fsize 1e20 -strand both -norm 10e7.   The data processing 
and generation of signal profile plots were performed as described for the 4sU-seq data.  
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Zebrafish single-embryo RNA-Seq 
Total nucleic acid was isolated from single embryo hemizygous transgenic prl3a and sibling 
embryos at 50 hpf. Total nucleic acid was treated with DNAseI (NEB, Catalogue number 
M0303L) and 12 replicates per genotype were processed. Ambion ERCC spike-in mix 2 (Cat. 
No. 4456740) was added to 200 ng RNA according to the manufacturer’s instructions and 
sequencing libraries were prepared using the Illumina TruSeq Stranded mRNA Sample Prep 
Kit. Libraries were pooled and sequenced on Illumina HiSeq 2500 in 75 bp paired-end mode. 
Sequencing data were assessed using FastQC and aligned to the GRCz10 reference genome 
and Ensembl 86 transcriptome using TopHat2. Read counts per gene were generated using 
htseq-count and used as input for pairwise differential expression analysis using DESeq2. All 
sequences are placed at ENA under the following IDs: ERS1447344, ERS1447360, 
ERS1447337, ERS1447351, ERS1447356, ERS1447361, ERS1447362, ERS1447330, 
ERS1447346, ERS1447366, ERS1447352, ERS1447358, ERS1447329, ERS1447353, 
ERS1447327, ERS1447339, ERS1447338, ERS1447342, ERS1447341, ERS1447363, 
ERS1447368, ERS1447334, ERS1447355, ERS1447348. GO enrichment analysis was carried 
out at: https://biit.cs.ut.ee/gprofiler/gost under default settings with the added option of “Ordered 
query”. 
Zebrafish single cell RNA-seq analysis 
Single cell RNA-seq data at 24 hpf was downloaded from the GEO database with accession 
number GSE112294 / GSM3067195 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM3067195) and uploaded to SPRING 
(https://kleintools.hms.harvard.edu/tools/spring.html) for clustering, analysis and generation of k-
nearest-neighbor graph following online instructions. The k-nearest neighbor SPRING plot was 
generated using 207 cells and 1092 genes using default settings. The same raw data 
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(GSM3067195_24hpf) was used to perform the GSEA analysis. Raw counts for cells belonging 
to clusters 139 (Neural Crest), 182 (Xanthoblasts), 183 (Melanoblasts), 184 (Iridoblasts) were 
extracted and sorted by prl3a expression with the following parameters (prl3a negative, log2 
prl3a counts <1; prl3a-positive, log2 prl3a counts ≥1). Differential expression between prl3a-
positive cells and prl3a-negative cells was performed using the scDE R package (v. 1.99.4) and 
the obtained list (ranked by Z-score) was used to check enrichment of VATPases genes using 
GSEA, http://www.broad.mit.edu/gsea/index.html. The V-ATPase genes query geneset was 
obtained from the zebrafish single-embryo RNA-Seq data.  
Global analysis of human melanoma patient samples 
The gene expression and prognosis of human melanoma patient samples used were 
downloaded from TCGA cBioPortal (https://www.cbioportal.org/); from GEO database for the 
Lund data set, GSE65904 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65904); 
and from European Genome-phenome Archive (EGA) database for the Leeds Melanoma 
Cohort (LMC) gene expression study (EGAD00010001561). Patient samples were ranked 
based on the PRL3 expression level. PRL3High and PRL3Low subgroups were defined with a 10% 
threshold for TCGA (n=366) and Leeds (703) and 25% threshold for the Lund dataset (stage III 
patients, n=124). For TCGA data, the whole transcriptomic expression values of PRL3-high and 
PRL3-low subgroups were retrieved from Genomic Data Commons (GDC, 
https://portal.gdc.cancer.gov). Comprehensive survival analysis of publicly available melanoma 
gene expression datasets were analysed using the SurvivALL R package (Pearce, 2017). The 
PRL3-low/PRL3-high groups were determined by assessing all possible cut-points using the 
survivALL R package, the cut-points with the lowest p-value are shown (Figure S6). High PRL3 
was not associated with outcome in the TCGA melanoma cohort, likely due to heterogeneity of 
patients, drug treatments and follow-up information limited to overall survival in this cohort (Liu 
et al., 2018). 
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QUANTIFICATION AND STATISTICAL ANALYSIS 
Statistical details of the experiments, n numbers, and dispersion and precision measurements 
can be found in the figure legends.  
Counts of dorsal melanocytes in the head and trunk region were performed either blinded or 
using the Cell Counter plugin on ImageJ Fiji. Statistics for regeneration assays were performed 
using GraphPad Prism 8. For all regeneration assays, a normal distribution and equal variance 
were assumed. For assays with more than two groups, data was analyzed through Analysis of 
variance (ANOVA), using Tukey’s multiple comparison test. For assays with two groups, an 
unpaired two-tailed Student’s t-test was used. For regeneration assay box plots: boxes 
represent 25th to 75th percentiles, lines are plotted at median. Whiskers represent Min to Max.  
For statistical analysis of the ChIP-seq data, read depths were quantified across all genes 
(whole gene body; ENSEMBL hs_GRCh38_p12) using the ‘annotatePeaks.pl’ function in the 
HOMER suite with the following parameters. -size "given" -len 0 -strand both -norm 10e7. All 
genes equal to, or greater than 10 kb in length were normalised across samples (per ChIP - e.g. 
DDX21) using the ‘normalizeQuantiles’ function in the limma R package. All subsequent 
statistical tests and plots (boxplots) were performed in R.    
Statistical Gene Ontology analysis: The ClusterProfiler R package (v. 3.10.1) with associated R 
packages was used to generate biological term classification and gene enrichment analysis as 
described (Yu, et al., 2012). The software Cytoscape was used to identify the predominant GO-
term clusters from the gene ontology analysis results (Shannon, et al., 2003). 
Lysotracker image analysis was done using ImageJ particle analysis. Optimal imaging 
conditions were selected using nuclei staining (particle analysis, threshold 84/255, >25 µm2 
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size). Lysotracker staining was determined by particle analysis (threshold 215/255, 0-infinity 
µm2 size, 0-1 circularity) in each cell, and lysotracker staining intensity was determined from the 
original image. Total area of all particles analysed per cells was plotted, and proportional 
intensity per cell was calculated using the formula: SUM(M*A)/SUM(A), where M is mean 
intensity per particle and A is area (µm2) of each particle. Width of lysotracker-positive particles 
were calculated using ImageJ, plot profile function, focusing on cross-sections over isolated 
individual particles. Quantification representative of 2 biological replicates. 
 
In situ hybridisations of mitfa in mitfavc7 background were analysed in Image J software. 
Channels were split and the green channel analysed. An area of somites/myotome between the 
lateral and dorsal stripes was selected for analysis, subtract background function was used 
specifying a rolling ball radius of 10 pixels and disable smoothing. Particle analysis was used to 
analyze mitfa-positive signal in each embryo (threshold 243/255, 4- infinity pixels^2 size, 0-1 
circularity). Mitfa-positive signal as a percentage of area was calculated by: SUM(Ai)/At, where 
Ai is the area of all mitfa-positive particles per area selected in an embryo, and At is the total 
area selected. Quantification representative of 2 biological replicates. 
Quantification of mitfa:GFP positive signal was done using ImageJ particle analysis in the green 
channel (threshold 60/255, 0-infinity, µm2 size, 0-1 circularity). Each peripheral nerve was 
analyzed independently, and GFP-positive signal located at the Dorsal Root Ganglion was 
excluded. To take into account slight variations in the distance embryos were plated from the 
bottom of the well, the GFP-positive signal was normalized: the sum of the total are of all GFP-
positive particles per peripheral nerve (measured in the green channel) was normalized by the 
mean peripheral nerve length per fish (measured in the red channel; Tg(nbt:dsRED)). 
Normalized GFP-positive area (pixels2) was plotted per peripheral nerve analyzed. 
Quantification representative of 3 biological replicates. 
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Figure S1, Related to Figure 1.
D
M
S
O
B
4-
R
ho
da
ni
ne
A B
25oC32oC
0 54 96 hpf
Photo
B4-Rh
25oC32oC
0 54 96 hpf
Count
B4-Rh
C
M
el
an
oc
yt
e 
co
un
ts
200200
150
100
50
0
Untr B4-Rh
PTU
70
Photo
8
D
ay
 7
B4-Rh
D
ay
 8
Untr
B4-RhUntr
B4-Rh
PTUPTU
B4-RhUntr.
B4-RhUntr
WashoutWashout
D
E
M
el
an
oc
yt
e 
co
un
ts
DMSO 
400
350
300
250
200
150
100
50
0
C
on
tro
l 
 P
TU
 C
on
tro
l 
B
4-
R
h 
P
TU
 B
4-
R
h 
Day 5
Photo
Supplemental Text and Figures
Figure S1. B4-Rhodanine is an enhancer of MSC regeneration in embryos and adults, 
Related to Figure 1. 
A. Images and B. quantification of DMSO and B4-Rhodanine treated mitfavc7 embryos in a MSC 
regeneration assay. Unpaired student’s t-test; ** p-value=0.0321. n=3 experimental repeats with 
at least 10 embryos/group 
C. Adult tail clips of B4-Rhodanine (1 μM) treated and untreated sibling controls. Melanocyte 
regeneration at day 5 post tail-clip. Individual melanocytes in the regenerating tail fin tissue were 
counted. Significance determined by unpaired student’s two-tailed t-test (p-value = 0.0001). n=3 
biological replicates. 
D, E. Adult tail clips of B4-Rhodanine (1 μM) treated and untreated sibling controls. A tail-clipped 
fish from each group was co-treated with 1-phenyl-2-thiourea (PTU). Melanocyte regeneration 
was imaged at days 7 and 8 post tail clip and counted at day 8 post tail clip following 24-hour 
washout. 
  
Figure S2, Related to Figure 2.
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Figure S2. prl3a and prl3b zebrafish genetics, Related to Figure 2. 
A. Phylogenetic tree of zebrafish, human and mouse PRL3 proteins constructed by DNAMAN. 
B, C.  Images and quantification of prl3a morpholino (MO) knock-down in mitfavc7 melanocyte 
regeneration assay. Student’s t-test; **** p-value<0.0001. n=3 experimental repeats, with at least 
10 embryos/ group. 
D. TALEN and CRISPR-Cas9 genetic mutations and predicted protein structures in prl3a and 
prl3b respectively. The TALEN recognition site/ CRISPR guide RNA target sequence is 
highlighted in yellow. The deleted region is highlighted in blue. 
E. Images of prl3a mutant and wild type control in mitfavc7 temperature regulated melanocyte 
regeneration. 
F. Quantification of melanocytes in the mitfavc7 regeneration assay of wild type or prl3a mutant 
embryos treated with DMSO or 20µM of B4-Rhodanine (B4-Rh) for 72 h prior to initiating 
regeneration. **** p-value<0.0001; Tukey’s multiple comparison test. 
G. Schematic image of prl3a Tol2 construct introduced into zebrafish. 
H. Images of live Tg(b-actin:prl3a) transgenic zebrafish embryos and WT sibling control at 48 hpf. 
Fewer melanocytes and Tg(cmlc2:eGFP) heart expression are indicated with black and green 
arrows, respectively. 
I. Images of a whole mount hybridization for mitfa of Tg(b-actin:prl3a) transgenic zebrafish embryo 
and wild type sibling control at 24 hpf. N= 12 for each group. 
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Figure S3. Characterization of PRL3 overexpressing cells, and controls for super 
resolution imaging and data processing, Related to Figure 3. 
A. A density plot showing the distribution of PRL3 expression over different human melanoma 
cell lines. RNAseq data (FPKM) from a large panel of human melanoma cell lines (45 from Cancer 
Cell Line Enclopedia and 20 from study EGAS00001000815) were retrieved and plotted. The 
geometric mean values for PRL3 across the melanoma cell line panel are annotated on the X-
axis.  
B. Western blot comparing the levels of PRL3 protein in cells stably expressing the empty vector 
(EV) or overexpressing PRL3 (PRL3o/e) compared with ß-TUBULIN. PRL3 protein is detected with 
an anti-PRL3 antibody. 
C. Normalized counts of PRL3 transcripts in EV versus PRL3 overexpressing cells using 4sU 
nascent RNA sequencing data. 
D. Growth curve analysis of EV and PRL3 overexpressing cells by SRB assay over a period of 3 
days. n=3 biological repeats, 6 technical replicates. Error bars = Standard deviation. 
E. FACS cell cycle analysis of EV and PRL3 overexpressing cells. n=2 biological repeats for each 
cell type. FACs traces are representative for each cell line. 
F. Comparison of images without super-resolution and with super-resolution reveal why PRL3 
complexes have not been previously detected as foci in the nucleus. Widefield (cells imaged 
without super-resolution) and SIM images (cells imaged with structured illumination super 
resolution microscopy) of C092 human melanoma cells that express endogenous PRL3. PRL3 
protein in magenta, DDX21 protein in green and DAPI in blue. Scale bars: 5 µm. 
 
G. SIM images of secondary antibody control without primary antibody staining of cells expressing 
empty vector (EV) and PRL3HA stained cells, DAPI staining in blue. All images were acquired 
using the same settings. Scale bars: 2µm.  
Figure S4, Related to Figure 4.
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Figure S4. Lysotracker analysis of vesicles, Related to Figure 4.  
A. Quantification of the number of distinct lysotracker-positive particles per cell. Significance 
determined by ANOVA using Tukey’s analysis for multiple comparisons; (* p-value = 0.0119; **** 
p-value < 0.0001).  Line and error bars represent mean and S.E.M. 
B. Box plot of vesicle diameters as determined by lysotracker staining and measured by 
ImageJ. Non-significance between groups was determined by ANOVA using Tukey’s analysis for 
multiple comparisons. Box represents 25th to 75th percentiles, line plotted at median. Whiskers 
represent Min to Max. Individual vesicles from cells expressing empty vector EV) n= 35; PRL3 n= 
40; PRL3(C104S) n=47. 
C. Acidic vesicle diameters measured by lysotracker intensity (Gray value) vs. distance (microns). 
Double headed arrows represent calculated vesicle diameters. 
 
  
Figure S5, Related to Figure 5.
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Figure S5. DDX21 and MITF ChIP-seq controls and analysis, Related to Figure 5. 
A. UCSC genome browser tracks of DDX21 ChIP-seq signal at DDX23, RPLP2 and ATP6V1G1 
(left panel) and the corresponding qPCR validation of gene expression between EV and PRL3o/e 
A375 cells (right panel). (*p< 0.05 and **p<0.01; students t-test) Error bars: SD. 
B. Density plot showing the distribution of MITF expression over different human melanoma cell 
lines. RNAseq data (FPKM) from a large panel of human melanoma cell lines (45 from Cancer 
Cell Line Enclopedia and 20 from study EGAS00001000815) were retrieved and plotted. The 
geometric mean values for MITF across the melanoma cell line panel are annotated as bars on 
the X-axis. The level of MITF expression in the A375 melanoma cell line is indicated. 
C. Quantitative PCR analysis of MITF target genes and control gene ACTB used for validation of 
the ChIP-MITF experiment. The graph shows the enrichment ratios between DNA purified from 
the ChIP-MITF and input DNA. Error bars: SD. 
D. Venn diagram shows substantial overlapping gene targets between the two MITF ChIP studies. 
Webster et al., 2014 MITF ChIP peak information was downloaded from GSE50681 and mapped 
to Ensembl gene entries by closest distance to perform target gene comparison (p value from 
Fisher's exact test). 
 
 
  
Figure S6, Related to Figure 7.  
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Figure S6. High expression of PRL3 is associated with stemness and is an independent 
predictor of melanoma-specific death at all stages, Related to Figure 7.  
A. GSEA plot show PRL3-high melanomas are enriched for genes that inhibit stem cell 
differentiation. Leading edge genes are indicated with genes shared between Lund and TCGA 
datasets indicated in red. GO: gene ontology. 
B, C. log10 p-value distribution from the optimal cut-off calculation via R package survivALL. 
Patient samples are ranked by PRL3 (PTP4A3) expression level from low to high. Each patient is 
represented by a dot in the graph. The cut-point with the lowest p-value is chosen to stratify the 
patient cohort. All significant cut-points (p < 0.05) are highlighted. Each event is shown by the 
black bar at the bottom x-axis. HR = Hazard Ratio. 
D. Beeswarm plot of PRL3 expression in Leeds cohort samples collected from patients at 
indicated melanoma stages. 
E. Kaplan-Meier survival curves of melanomas patients diagnosed Stages I, II and III in the Leeds 
cohort. Later stage diagnosis is associated with worse melanoma-specific survival.  
F. Violin plot of PRL3 expression in Lund patient samples collected from primary and metastatic 
tissue sites.  
G. Kaplan-Meier survival curves demonstrate that PRL3-high melanomas are associated with 
worse melanoma-specific survival in the Lund Stage III sub-cohort. The PRL3-low/PRL-high 
groups were determined as in Figure 7. 
H. Cellular compartment (CC) gene ontology terms enriched in the Lund Stage III PRL3-Low 
group comparing to the PRL3-High group. All CC enrichment terms relate to vesicle components. 
NES: normalised enrichment score. FDR q-val: false discovery rate q values. 
Supplementary Video legend: 
Supplementary Video 1. Regenerating melanocyte develop from deep precursors within 
the embryo, Related to Figure 1. 
Zebrafish embryos treated with NFN1 (left-hand panel) and NFN1 plus B4-Rhodanine (Right-
hand panel). Regenerating melanocytes can be observed using melanin as a lineage tracer 
(black). Regenerating melanocytes are observed to develop from deep within the embryos, with 
the first emerging melanocytes occurring at similar times post-washout, but with many more 
melanocytes emerging in the B4-Rhodanine treated embryo. Embryo also expresses 
Tg(sox10:GFP), and GFP expression was not observed to change between treatment groups. 
 
  
Supplemental Table Titles 
Table S1: DDX21 Mass spec peptides, Related to Figure 3. 
Table S2: DDX21 phospho-sites, Related to Figure 3. 
Table S3: 4sU_4sUpaused_ChIP data summary, Related to Figures 4 and 5. 
Table S4: Enrichment analysis of DDX21_PRL3 overlapping genes, Related to Figure 5. 
Table S5: gProfiler_drerio_all_results, Related to Figure 6. 
Table S6: GSEA in patient cohorts, Related to Figure 7. 
Table S7: Oligonucleotide Table, Related to STAR Methods. 
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